Unnamed: 0,patient_filename,t,text,type,n,cmem_n_reasoning,cmem_n_ans_str,cmem_n_num_update
756,TCGA-AN-A0FF.9B4BA15D-A071-4213-AD2C-075A04ED48CD,0,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 1 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,"The N stage indicates the presence or absence of lymph node involvement. In this report, it is stated that the N stage is 0, which means that no lymph nodes were involved in the cancer. This information is consistent with an N0 stage.",N0,0.0
791,TCGA-AO-A0J5.5EFC16F4-7FC7-479E-93F7-AEDC2D350A22,3,"Clinical Diagnosis & History: year old female with stage IV breast carcinoma, debulking surgery. Specimens Submitted: 1: SP: Right breast and axillary contents level 1. DIAGNOSIS: 1. BREAST, RIGHT; MODIFIED RADICAL MASTECTOMY: - INVASIVE CARCINOMA, HISTOLOGIC GRADE II/III (MODERATE TUBULE. FORMATION) TO HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION). NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND SHAPE), MEASURING AT. LEAST 10 CM IN LARGEST DIMENSION GROSSLY. INVASIVE CARCINOMA SHOWS. MICROPAPILLARY FEATURES. FOCAL EXTRACELLULAR MUCIN IS ALSO NOTED. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID CRIBRIFORM. MICROPAPILLARY AND FLAT TYPES, WITH HIGH NUCLEAR GRADE, AND EXTENSIVE. NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN ALL FOUR QUADRANTS. - THE DCIS IS LOCATED IN ALL FOUR QUADRANTS. - THE NIPPLE IS INVOLVED BY INVASIVE CARCINOMA. - CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE CARCINOMA. - VASCULAR INVASION IS PRESENT. - THE SKIN IS INVOLVED BY INVASIVE CARCINOMA BY DIRECT EXTENSION INTO THE. DERMIS. - THE ATTACHED SKELETAL MUSCLE IS EXTENSIVELY INVOLVED BY INVASIVE CARCINOMA. BY DIRECT EXTENSION. - INVASIVE CARCINOMA IS CLOSE (LESS THAN 0.1 CM) FROM THE NEAREST DEEP. MARGIN. THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. FOCAL CHANGES OF PRIOR PROCEDURE ARE NOTED IN THE AXILLARY TAIL. - METASTATIC CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES. (2/2) ADDITIONAL SECTIONS OF THE AXILLARY TISSUE HAVE BEEN SUBMITTED AND. THE FINDINGS WILL BE REPORTED IN AN ADDENDUM. - NUMEROUS FOCI OF METASTATIC CARCINOMA ARE NOTED IN THE AXILLARY SOFT. TISSUE, WITH THE LARGEST MEASURING AT LEAST 1.4 CM. Immunohistochemical stains were performed on formalin-fixed tissue with. the following results for invasive carcinoma (block 1-8): ESTROGEN RECEPTOR. 90% nuclear staining with strong. intensity. PROGESTERONR RECERTOR. Negative (no nuclear staining). HER2. Equivocal (focal 2+). FISH will be performed. (5% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). The carcinoma is positive for E-cadherin, supporting lobular. differentiation. Comment: Controls are satisfactory. Ventana' a PATHWAY anti-HER-2/neu is. an FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed. against the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25(1):118-145). The ER and PR rabbit monoclonal antibodies are also FDA. approved. Some of the imnunohistochemistry and ISH tests were developed and their. performance characteristics were determined by the Department of Pathology. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88). as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: M.D. M.D. 1) The specimen is received fresh labeled, ""right breast and axillary. contents level 1"",. It consists of a breast with attached. axillary contents. The breast measures 20 x 15 x 5 cm with overlying skin. ellipse measuring 18 x 7 x 0.2 cm. Situated centrally on the skin surface is. a. fixed, and retracted nipple measuring 1.5 x 1.0 x 1.0 cm. The surrounding. skin is markedly thickened (up to 0.6 cm) . A suture demarcates the axillary. contents which measures 7 x 5 x 2 cm. The posterior surface of the breast is. inked black and the anterior blue. Part of the posterior surface of the. breast is covered by dark red skeletal muscle, measuring 11 x 4 x 0.5 cm. The specimen is serially sectioned to reveal an irregular tumor bed (10 x. 8.3 x 5.1 cm) with poorly defined white, firm and tan areas. The tumor bed. occupies almost the entire breast volume, extending throughout all four. quadrants. The tumor bed is located 0.2 cm from the posterior margin, 0.3 cm. from the anterior margin, and 0.5 cm from the skeletal muscle. The remaining. breast tissue shows yellow fatty areas with foci of fibrosis. The axillary. tissue is dissected to reveal 13 possible lymph nodes, ranging in size from. 0.4 cm to 1.2 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. The specimen is photographed. Tissue is. submitted to TPS. Summary of sections: N - nipple, nipple base and tumor. s - thickened skin. PM - posterior margin. AM - anterior margin. DSM - deep skeletal muscle. T - tumor central region and closest margins, continuous cross sections,. taken from medial to lateral. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 - axilla, level one lymph nodes. AX axillary tail, entirely submitted. Summary of Sections: Part 1: SP: Right breast and axillary contents level 1. Block. Sect. Site. PCs. 1. AM. 1. 11. ax. 11. 1. DSM. 1. 9. L1. 9. 2. LIQ. 2. 2. LOQ. 2. 3. N. 3. 1. PM. 1. 1. s. 1. 10. T. 10. 2. UIQ. 2. 2. UOQ. 2. Procedures/Addenda: Addendum. Date Complete: By: 1. Addendum Diagnosis. PART #1. RIGHT BREAST AND AXILLARY CONTENTS: THE REMAINING AXILLARY TISSUE IS ENTIRELY SUBMITTED. NO ADDITIONAL LYMPH. NODES ARE IDENTIFIED. ,MD.",BRCA,1,"The report states that 'METASTASIS CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES (2/2)' and 'NUMEROUS FOCI OF METASTASIS CARCINOMA ARE NOTED IN THE AXILLARY SOFT TISSUE, WITH THE LARGEST MEASURING AT LEAST 1.4 CM'. These findings indicate that the cancer has spread to multiple lymph nodes, which is consistent with an N3 stage.",N3,0.0
604,TCGA-A7-A5ZX.A8834D03-81F5-43BC-A4AB-F215C89CB095,1,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Lymph nodes, left axillary sentinel, excision -. Metastatic carcinoma in two of two (2/2) lymph nodes in this part. B. Breast, right, excision -. Invasive lobular carcinoma, 0.5 cm in greatest dimension (see. microscopic description, including for prognostic marker results) . Lobular carcinoma-in-situ. Fibrocystic changes, with microcalcifications present. Skin, nipple, and deep margin negative for tumor. C. Breast, left, excision -. Invasive lobular carcinoma, forming a 3.2 cm in greatest dimension. mass, with additional scattered foci of invasive lobular carcinoma. present. Invasive lobular carcinoma present at least very near (<1 mm from), and. possibly at, the deep margin in the separate foci. Skin and nipple negative for malignancy. Lobular carcinoma-in-situ. Biopsy site changes. Fibrocystic changes, with microcalcifications present. D. Lymph nodes, left axillary, excision. Metastatic carcinoma in nineteen of twenty-two (19/22) lymph nodes in. this part, including with metastatic carcinoma in the superior-most. lymph node. Microscopic Description: A,D. There is metastatic carcinoma in two of two (2/2) sentinel lymph. nodes in part A, and in nineteen of twenty-two (19/22) lymph nodes in. part D. Thus overall in this case, there is metastatic carcinoma in. twenty-one of twenty-four (21/24) lymph nodes (pN3a) There is. extracapsular extension. The largest involved lymph node is one of the. sentinel lymph nodes, 2.5 cm in greatest dimension. The largest lymph. node in part D is negative for tumor. There is metastatic carcinoma in. the superior-most lymph node in part D. Please note that in addition. to examining H&E stained sections, immunostains with antibodies to. keratin (AE1-AE3) were examined on representative blocks in both parts. to aid in assessment. B. The following template summarizes the findings in this part: Invasive carcinoma: Present. Histologic type: Invasive lobular carcinoma, identified. incidentally in block B4. Histologic grade : Overall grade: 2. Architectural score: 3. Nuclear score: 2. Mitotic score: 1. Greatest dimension (pT) : slightly >0.5 cm (pT1b). Specimen margins: Negative. Vessel invasion: Not identified. Nipple: Negative for tumor. Invasion of skin or chest wall: Not identified. Ductal carcinoma in situ: Not identified. Description of non-tumorous 'breast: Fibrocystic changes, with. microcalcifications present. Comments: There is also lobular carcinoma-in-situ present. Please note. that immunostains with antibodies to p63, keratin (AE1-AE3), and. e-cadherin were examined on representative blocks to aid in assessment. Distant metastasis (pM) : Not applicable. Breast prognostic marker results. Estrogen receptor: 80% / moderate intensity. Progesterone receptor: 5% / weak intensity. Her2 by IHC: 1+. Interpretation. Estrogen receptor: Positive. Progesterone receptor: Weakly positive. Her2 by IHC: Negative for Her2 expression. Comments. Fixation time : 30:00. Cold ischemia time: 0:30. The analyzed tissue met quality requirements of the ASCO/CAP guidelines. for Her2 testing. Control materials stained appropriately. Based on data collected in our laboratory and reported in the. literature we recommend FISH analysis for Her2 in cases that stain with. intermediate intensity by immunohistochemistry. Prognostic markers were done by immunohistochemical stain on paraffin. sections from 10% neutral buffered formalin fixed tissue using. antibodies on a Benchmark automated stainer. The Her2 antibody is clone 4B5 and has been approved by the FDA as an. aid in the assessment of breast cancer patients for whom Herceptin. treatment is considered. This laboratory meets the test validation and quality assurance. requirements of the ASCO/CAP guidelines for Her2, ER and PR testing for. carcinoma of the breast. C. The following template summarizes the findings in this part: Invasive carcinoma: Present. Histologic type: Invasive lobular carcinoma. Invasive lobular. carcinoma is identified comprising the main mass lesion, as well as in. multiple additional foci in random sections of this breast (blocks C7,. C8, C10, C11). Histologic grade: Overall grade: 2. Architectural score: 3. Nuclear score: 2. Mitotic score: 1. Greatest dimension (pT) : The main mass lesion is 3.2 cm in. greatest dimension (pT2). Specimen margins: Although the margins surrounding the main mass. lesion are negative, tumor in the additional foci of invasive lobular. carcinoma is present at least very near (<1 mm from). and possibly at,. the deep margin, with fragmentation hindering assessment. Vessel invasion: Not identified. Nipple: Negative for tumor. Invasion of skin or chest wall: Not identified. Ductal carcinoma in situ: Not identified. Description of non-tumorous breast: Fibrocystic changes, with. microcalcifications present. Biopsy site changes. Comments: There is also lobular carcinoma-in-situ present. Please note. that immunostains with antibodies to keratin (AE1-AE3), and e-cadherin. were examined on representative blocks to aid in assessment. Distant metastasis (pM) : Not applicable. Prognostic markers: Previously performed. Note: have reviewed this case. [A few of the antibodies used in our laboratory may be classified as. analyte specific reagents. These antibodies are monitored and. controlled in our laboratory and their performance for in vitro. diagnosis is well described in the medical literature. They have not. been cleared or approved by the FDA.]. Specimen. A. Left axillary sentinel node. B. Right breast. C. Left breast. D. Left axillary contents. Clinical Information. CLINICAL HISTORY: yo white female with invasive lobular cancer left. breast. Intraoperative Consultation. A. Metastatic carcinoma present. Gross Description. A. Received fresh in a container labeled ""left axillary sentinel node"". is a portion of tissue which is tan-yellow and fatty externally. On. palpation, it appears to consist of two adherent lymph nodes, spanning. an area 2.5 x 1 X 0.5 cm and 1.8 x 1 X 0.4 cm. On cut surface, both. vary from soft and tan to yellow, to firmer and tan-white. The. specimen is entirely submitted for frozen section in two blocks, with. one lymph node per block. B. Received fresh (excised at. placed in. formalin at. in a container labeled ""right breast"" is a 21 cm from. superior to inferior x 18 cm from medial to lateral x 3.2 cm from. anterior to posterior soft tan-yellow mastectomy specimen, with an. orienting suture present. On the anterior surface there is a 7. X 4.4. cm. tan-white skin ellipse, with a centrally located 1.3 X 1.3 x 1 cm. nipple. The intact deep margin is inked, and the specimen is serially. sectioned. On cut surface, the specimen consists of interspersed. yellow adipose tissue and tan tissue, without focal lesion. RS-10,. following fixation. BLOCK SUMMARY: B1,B2 - upper outer quadrant; B3,B - upper inner. quadrant; 85,B6 - lower inner quadrant; B7,B8 - lower outer quadrant;. B9 - central breast; B10 - nipple. C. Received fresh (excised at. placed in. formalin at. in a container labeled ""left breast"" is a 20.5 cm. from superior to inferior x 18.8 cm from medial to lateral x 3.2 cm. from anterior to posterior soft tan-yellow mastectomy specimen, with an. orienting suture present. On the anterior surface there is a 7 X 5 cm. tan-white skin ellipse, with a centrally located 1.2 x 1.2 x 0.5 cm. nipple. The intact deep margin is inked, and the specimen is serially. sectioned. There is a circumscribed 3.2 x 2.9 X 1.8 cm rubbery. tan-white mass within the upper outer quadrant. The lesion is 1.1 cm. from the deep margin, and 1.3 cm from the anterior surface, which is. subsequently inked blue. The specimen away from the nodule consists of. interspersed yellow adipose tissue and tan tissue, without additional. focal lesion. RS-12, following fixation. BLOCK SUMMARY: C1-C3 - tumor to anterior surface; C4,C5 - tumor to deep. margin; C6 - central tumor; C7 - upper outer quadrant; C8 - upper. inner quadrant; C9 - lower inner quadrant; C10 - lower outer quadrant;. C11 - central breast; C12 - nipple. D. Received fresh in a container labeled ""left axillary contents"" is a. 6.5 x 6.3 x 2.4 cm aggregate of yellow lobular fatty tissue which has a. suture designating superior axilla. Dissection of the specimen reveals. multiple lymph nodes, up to 3.5 cm in greatest dimension. RS-9,. following fixation, with all lymph nodes submitted, from superior to. inferior, with the superior-most lymph node in block D1, four lymph. nodes in block D2, five lymph nodes in block D3, three lymph nodes in. block D4, one sectioned lymph node in blocks D5 & D6, four lymph nodes. in block D7, one lymph node in block D8, and three lymph nodes in block. D9.",BRCA,3,The report states that there is metastatic carcinoma in nineteen of twenty-two (19/22) lymph nodes in the left axillary region. This information indicates that the N stage is N3.,N3,0.0
592,TCGA-A7-A3RF.4AF67A51-97C1-4D58-9E60-03FDFFACD38A,1,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Left axillary sentinel nodes, excision: 2 lymph nodes negative for. metastatic disease, 0/2. B. Left breast mass, excision: Invasive mucinous carcinoma, Elston SBR. grade 2. Tumor is less than 1 mm from the deep margin and at least. extremely close to the lateral margin. C. Pectoralis fascia, excision: Adipose tissue and skeletal muscle. present. Mucinous carcinoma present in the adipose tissue at the inked. medial margin of resection. Microscopic Description: A. 2 sentinel nodes are present examined in their entirety at multiple. levels. They are both negative for metastatic disease, 0/2. B. This excision discloses invasive mucinous adenocarcinoma. Of note,. it has a higher nuclear grade the usual mucinous carcinoma. Also,. particularly in block #5, there was a suspicion for lymphatic invasion. This is considered not to be the case, however, based on stains for. D240 and CD34. The negative staining for p63 also helps to exclude in. situ tumor. Please see the template below: Invasive Carcinoma: Histologic type: Invasive mucinous carcinoma. Histologic grade: Elston SBR grade 2. Overall grade: Architectural score: 2. Nuclear score: 3. Mitotic score: 1. Greatest dimension (pT): 3.7 cm, pT 2. Specimen margins: Tumor is present less than 1 mm from the. deep margin and at least extremely close to the lateral margin. Vessel invasion: Negative. Calcification: Rare. Description of non-tumorous breast: No significant pathology. Comments: Attached skin negative for tumor. Prognostic markers: Previously performed. C. Microscopic examination performed. Specimen. A. Left axillary sentinel node. B. Left breast mass, long anterior, short superior. C. Pectoralis/posterior, long anterior short superior. Clinical Information. PRE-OP DIAGNOSIS: Left breast cancer. HISTORY: -year-old white female with left mucinous breast cancer. Gross Description. A. Received fresh labeled ""left axillary sentinel node"" are 2 soft tan. gold-pink tissues averaging 1.8 cm in greatest dimension. The. specimens are bisected and entirely submitted independently in. 2. blocks. B. Received fresh for tissue procurement within a. container. labeled ""left breast mass"" is a 7.5 cm (medial to lateral) by 5.0 cm. (superior to inferior) by 4.2 cm (anterior to posterior) soft,. lobulated tan gold-white portion of fibroadipose tissue with 2 sutures. as stated previously. A 2.7 x 1.3 cm wrinkled tan-white portion of. skin is present along the anterior aspect. The margins are inked as. follows: Anterior blue, posterior black, superior green, and inferior. orange. The specimen is sectioned from medial to lateral. There. is. a. well-circumscribed, 3.7 cm (medial to lateral) by 3.2 cm (superior to. inferior) by 2.7 cm (anterior to posterior) rubbery tan white mucinous. tumor mass within the lateral half of the specimen. A portion of tumor. and a portion of normal parenchyma are submitted for tissue procurement. as requested. The tumor focally extends to within less than 0.1 cm of. the inked posterior margin. Several cylindrical tan-white structures. in keeping with those associated with needle core biopsy are present. The remaining cut surfaces consist predominantly of soft, lobulated tan. gold adipose tissue with a scant amount of interspersed delicate. Fan-white fibrous tissue. Summary: 1 - perpendicular sections medial margin, 2 through 9 -. sequential sections, 10 - perpendicular sections lateral margin. Specimen is fixed at. C. Received fresh labeled ""pectoralis fascia posterior"" is a 3.0 cm. (superior to inferior) by 2.5 cm (medial to lateral) by 0.7 cm anterior. to posterior) soft, lobulated tan gold-white portion of fibroadipose. tissue with 2 sutures as stated previously. The margins are inked as. follows: Anterior blue, posterior black, medial green, and lateral. orange. The specimen is sectioned from superior to inferior. The cut. surfaces consist predominantly of soft, lobulated tan gold adipose. tissue with a scant amount of interspersed delicate tan-white fibrous. tissue. No residual mass lesion or abnormality is identified grossly. Summary: 1 - perpendicular sections superior margin, 2 through 4. sequential sections, 5 - perpendicular sections inferior margin. Specimen is fixed at.",BRCA,0,"The report states that both sentinel nodes were negative for metastatic disease, indicating an N0 stage.",N0,1.0
1101,TCGA-BH-A6R9.1DB8FAFB-FC4A-4401-8316-30FB5352335D,1,"FINAL DIAGNOSIS: BREAST, LEFT, TOTAL MASTECTOMY (120.1 GRAMS) -. A. METAPLASTIC CARCINOMA OF THE BREAST, SPINDLE CELL TYPE, NOTTINGHAM GRADE II (TUBULE. FORMATION 3, NUCLEAR PLEOMORPHISM 3, MITOTIC ACTIVITY 1; TOTAL SCORE 7/9). B. THE INVASIVE TUMOR MEASURES 3.8 CM IN GREATEST DIMENSION. C. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. D. INKED MARGINS ARE NEGATIVE FOR CARCINOMA; HOWEVER, A FOCUS OF INVASIVE CARCINOMA IS LESS. THAN 1.0 MM (LESS THAN 0.1 CM) FROM THE ANTERIOR INKED MARGIN. E. THE INVASIVE CARCINOMA IS LOCATED IN THE CENTRAL AREA. F. THE NIPPLE DERMIS AND ADJACENT SKIN DERMIS, BUT NOT THE EPIDERMIS, ARE INVOLVED BY INVASIVE. CARCINOMA. G. NIPPLE DUCTS WITH SQUAMOUS METAPLASIA. H. PREVIOUS BIOPSY SITE CHANGES. I. THE INVASIVE TUMOR CELLS ARE NEGATIVE FOR ESTROGEN RECEPTOR, WEAKLY POSITIVE FOR. PROGESTERONE RECEPTOR, AND NEGATIVE FOR HER-2, AS PER PREVIOUS PATHOLOGY REPORT. (see comment). J. NON-NEOPLASTIC BREAST WITH RADIAL SCARS. COMMENT: Due to the weakly positive PR result on the core biopsy based on stains performed at. hormone. receptor immunohistochemistry will be repeated and an addendum will follow. Addendum. BREAST TUMOR IMMUNOHISTOLOGY RESULTS. HORMONE RECEPTOR IMMUNOHISTOCHEMISTRY. H SCORE. RAW IMMUNOSTAINING SEMIQUANTITATION. ER: Weakly positive. 10. (0: 91%; 1+: 8%; 2+: 1%; 3+: 0%). PR: Negative. o. (0: 100%; 1+: 0%; 2+: 08; 3+:0%). ESTROGEN/PROGESTERONE RECEPTORS (ER/PR) TEST DETAILS: Using formalin fixed tissues (8-96 hours) and appropriate. positive and negative internal/external controls; the test for the presence of hormone receptor protein is performed by the. immunoperoxidase method according to the ASCO-CAP Guidelines. A positive Estrogen or Progesterane receptor tumor shows. nuclear immunostaining in greater than or equal to 1% of the tumor cells (i.e. and H-score of 1 or higher). The ER and PR. Histologic Score (H-Score, or HS) is calculated as the sum of intensity of staining times the proportion of cells staining and has a. dynamic range of 0 to 300. The semiquantitation immunostaining raw data used to calculate the H-score is also shown above in. the report. Generally, the H-score correlates to percentage of positive cells. According to. the correlation of mean H-score versus percent cells staining for ER is as follows: H-score of 251 (>75% cells staining); H-. score of 130 (51-75% cells staining); H-score of 42 (10-50% cells staining); H-score of 4 (<10% cells staining). Estrogen receptor antibody SP1, an IVD, is performed using the. Progesterone receptor antibody 1E2, an IVD, is performed using the. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Simple mastectomy. Central subareolar. SIZE OF TUMOR: Maximum dimension invasive component: 38 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Metaplastic carcinoma. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 7. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMALLYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 1 mm. PAGET'S DISEASE OF NIPPLE: LYMPH NODES EXAMINED: 0. METHOD(S) OF LYMPH NODE EXAMINATION: Other: None. SKIN INVOLVED (ULCERATION): T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pNX. M STAGE: Not applicable. ESTROGEN RECEPTORS: negative. PROGESTERONE RECEPTORS: positive, H-score: 60. HER2/NEU: 0. MICROSCOPIC: Block 1B: Antibody/Antigen. Vimentin. Positive. S-100. Rare weakly positive cells. CK5. Positive. AE1/AE3. Weakly positive. CK17. Positive. P63. Positive. CK14. Positive. Block 1C: Antibody/Antigen. P63. Highlights tumor cells and myoepithelial cells. Smooth muscle myosin heavy chain Highlights myoepithelial cells. Utilizing formalin-fixed (8-96 hour range), paraffin embedded tissue, immunohistology is. performed with the following selected antibodies and designated antibody clone (s), directed. against the following antigenic target (s), with adequate positive and negative internal and. external controls. Antibodies are optimized appropriate for fixation times. ANTIBODY. CLONE. TARGET ANTIGEN. VENDOR. Vimentin. V9. Mesenchymal cells. S-100. Polyclonal Rabbit. Melanoma screen. CK 5. XM26. High molec wt keratin. AE1/AE3. AE1/AE3. carcinomas. CK 17. E3. High molec wt keratin. p63. 4A4. Myoepithelial cells. CK 14. LL002. High molec wt keratin. Myosin. SMMS-1. Myoepithelial cells.",BRCA,0,"The report does not provide information about the involvement of lymph nodes in this patient's breast cancer. Therefore, the N stage cannot be determined based on the given information.",NX,2.0
801,TCGA-AO-A0JF.D58E5D64-B5B9-4487-8E46-225AE3617C14,0,"Clinical Diagnosis & History: 1.2. cm invasive duct carcinoma left breast upper outer quadrant (on core. biopsy) for left wide excision SLNB, possible left ALND. Specimens Submitted: 1: SP: Sentinel node #1 level one left axilla (fs). 2: SP: Sentinel node #2 level one left axilla (fs). 3: SP: Excision of tumor left breast two o'clock. 4: SP: Superior margin left breast. 5: SP: Medial margin left breast. 6: SP: Inferior margin left breast. 7: SP: Lateral margin left breast. 8: SP: Non-sentinel node left axilla. 9: SP: Posterior margin left breast. 10: SP: Levels one and two left axillary contents. DIAGNOSIS: 1. LYMPH NODE, SENTINEL #1, LEVEL I, LEFT AXILLA; EXCISION: - METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 5 MM IN GREATEST DIMENSION. - NEGATIVE FOR EXTRACAPSULAR EXTENSION. 2. LYMPH NODE, SENTINEL #2 LEVEL I LEFT AXILLA; EXCISION: METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 6 MM IN GREATEST DIMENSION. - EXTRACAPSULAR EXTENSION (>2MM) IS PRESENT. 3. BREAST, LEFT, 2 O'CLOCK; EXCISION: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE II/III. (MODERATE TUBULE FORMATION), NUCLEAR GRADE I/III (SLIGHT OR NO VARIATION IN. SIZE AND SHAPE), MEASURING 2.0 CM IN LARGEST DIMENSION MICROSCOPICALLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH LOW TO. INTERMEDIATE NUCLEAR GRADE. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - CALCIFICATIONS ARE PRESENT IN THE INVASIVE CARCINOMA ONLY. FOCAL VASCULAR INVASION IS PRESENT. FOR SURGICAL MARGINS SEE PARTS 4-7, AND 9. THE NON-NEOPLASTIC BREAST TISSUE THE NON-NEOPLASTIC BREAST TISSUE. SHOWS BIOPSY SITE CHANGES. RESULTS OF 108, PR, HER2-NEU) ARE AS FOLLOWS: ESTROGEN RECEPTOR. 95% nuclear staining with inhensity. PROGESTERONE RECEPTOR. 70% nucl. ith moderate intensity. HER2. Negative (1+). (<5% of invasive tumor cells exhibit weak complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). Comment: Controls are satisfactory. PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 485) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 4. BREAST, LEFT, SUPERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH PROLIFERATIVE FIBROCYSTIC CHANGES. 5. BREAST, LEFT, MEDIAL MARGIN; EXCISION: BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 6. BREAST, LEFT, INFERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 7. BREAST, LEFT, LATERAL MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. LYMPH NODE, NON-SENTINEL, LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODK (0/1). 9. BREAST, LEFT, POSTERIOR MARGIN; EXCISION: BENIGN BREAST TISSUE PREDOMINANTLY COMPOSED OF FIBROADIPOSK. ELEMENTS. SKELETAL MUSCLE TISSUE ALSO PRESENT. 10. LYMPH NODES, LEFT AXILLARY CONTENTS, LEVELS ONE AND TWO, EXCISION: ELEVEN BENIGN LYMPH NODES (0/11). Some of the mmunohistochemistry and. :ests were developed and their. performance characteristics were determined by. They have not been cleared or approved by the US FOO ana urug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88) as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES - (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1. 1) The specimen is received fresh for frozen labeled, ""Sentinel node #1,. level 1, left axilla"", and consists of one fatty lymph node measuring 2.5 x. 1.5 x 1.5 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fac -- lymph node frozen section control. RS- remaining lymph node. 2) The specimen is received fresh for frozen labeled, ""Sentinel node #2,. level 1, left axilla"", and consists of one fatty lymph node measuring 2.4 x. 1.5 x 1.2 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fsc -- lymph node frozen section control. RS- remaining lymph node. 3) The specimen is received unoriented and fresh, labeled ""excision of. tumor, left breast two o' clock"" and consists of a piece of fibrofatty. breast tissue measuring 5.2 x 5.0 x 2.3 cm. The specimen is entirely inked. black. Serial sectioning reveals a spiculated, white mass measuring 1.2 x. 1.2 x 1.1 cm. Sectioning through the remaining breast tissue reveals yellow. adipose tissue. A clip is identified. The tumor is entirely submitted and. the remaining tissue is representatively submitted and a small portion is. given to TPS. Summary of sections: MT - tumor and closest tissue edge. T - tumor (clip was in block 2). SS - serial sections remaining tissue. 4) The specimen is received fresh, labeled ""superior margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 5.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 5) The specimen is received fresh, labeled ""medial margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 3.2 x 2.5 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 6) The specimen is received fresh, labeled inferior margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 4.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 7) The specimen is received fresh, labeled ""lateral margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 4.4 x 2.8 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 8) The specimen is received in formalin, labeled ""Non-sentinel node left. axilla"" and consists of a single pink tan fatty lymph node measuring 0.9 cm. The lymph node is bisected and entirely submitted. Summary of sections: BLN-bisected lymph node. 9). The specimen is received fresh, labeled ""posterior margin, left breast"". and consists of a piece of fibrofatty breast tissue measuring 4.2 x 3.0 cm,. and 0.5 cm thick. The specimen is unoriented, entirely inked black. sectioned and submitted in its entirety. Summary of sections: SS - sequential sections. 10) The specimen is received fresh labeled ""levels one and two left axillary. contents"" It consists of a fragment of yellow adipose tissue measuring 12.5. x 10.5 x 2.8 cm. The levels are not designated. Numerous lymph nodes are. identified ranging in size from 0.4 cm up to 2.0 cm, and all are submitted. Summary: RLN-representative lymph node (multiple). ARLN-additional representative lymph nodes. LN-lymph nodes. Summary of Sections: Part 1: SP: Sentinel node #1 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 2: SP: Sentinel node #2 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 3: SP: Excision of tumor left breast two o'clock. Block. Sect. Site. PCs. 1. MT. 1. 1. SS. 1. 2. T. 2. Part 4: SP: Superior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 5: SP: Medial margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 6: SP: Inferior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 7: SP: Lateral margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 8: SP: Non-sentinel node left axilla. Block. Sect. Site. PCs. 1. bln. 1. Part 9: SP: Posterior margin left breast. Block. Sect. Site. PCs. 6. ss. 6. Part 10: SP: Levels one and two left axillary contents. Block. Sect. Site. PCs. 5. arln. 5. 5. LN. 12. 4. RLN. 4. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME. Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) : Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME.",BRCA,1,"The report states that there is metastatic adenocarcinoma in sentinel nodes #1 and #2, indicating lymph node involvement. The presence of extracapsular extension in node #2 further indicates N2 stage according to the AJCC staging system for breast cancer.",N2,2.0
1481,TCGA-OL-A66J.D5DE4BB3-81AC-44CB-9336-060F324C7A2F,0,"FINAL PATHOLOGIC DIAGNOSIS. A. Lymph node, sentinel #1, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). - Biopsy site changes identified. B. Lymph node, sentinel #2, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). C. Lymph node, sentinel #3, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). D. Lymph node, sentinel #4, right axillary, excision: - One lymph node, negative for metastatic carcinoma (0/1). E. Breast, right, partial mastectomy: - Invasive lobular carcinoma, see breast pathologic. parameters. - Margins of excision free of tumor, distance to the closest margin >2 mm. to superior and anterior. - Lobular intraepithelial neoplasia (LCIS), classic type. - Atypical ductal hyperplasia. - Previous biopsy site identified with extensive fat necrosis. - Flat epithelial atypia, focally associated with microcalcifications. - Sclerosing adenosis, focally associated with microcalcifications. - Microcalcifications in benign ductal and stroma. - Fibrocystic changes with cystic apocrine metaplasia. F. Breast, additional superior medial margin, excision: - Focal atypical ductal hyperplasia. - Lobular intraepithelial neoplasia (ALH/LCIS). - Focal flat epithelial atypia. to Sclerosing adenosis focally associated with microcalcifications. - Microcalcifications in benign ductules and stroma. - Fibrocystic changes with cystic apocrine metaplasia. - Duct ectasia. Breast Pathologic Parameters. Specimen E: Breast, right, partial mastectomy. 1. Invasive carcinoma: A. Size: Gross measurement: 1.6 x 1.5 X 1.4 cm. B. Composite histologic (modified SBR) grade II. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated lobular intraepithelial neoplasia (LCIS): - Within main mass (forming <5% of tumor volume). - Extending away from main mass. 3. Excisional biopsy margins: Free of tumor. - Invasive carcinoma > 2 mm from anterior and superior margins. - Additional margins greater than 3 mm away. 4. Blood vessel and lymphatic invasion: Not definitively identified. 5. Axillary lymph nodes: Negative for tumor (0/4). 6. Special studies (see. - Strong expression of ER in 90% of invasive tumor nuclei. - Strong expression of PR in 50% of invasive tumor nuclei. - Her2/neu antigen (FISH) Not amplified. Ratio 1.5. 7. pTNM: pT1c, NO(sn), MX. Clinical History: The patient is an. year old female with a history of biopsy proven grade Il. ILC of the right breast who undergoes right breast needle localization. lumpectomy and right axillary sentinel node dissection. Most recent breast. imaging on. showed in the right breast at the 10 o' clock position an. irregularly shaped heterogenous enhancing mass with irregular margins and. metallic clip artifact at mid depth measuring 1.4 X 1.2 X 1.2 cm representing. the biopsy proven malignant lesion. Posterior to that main mass was a focal. non-mass like enhancement measuring 1.6 x 1.1 cm suspicious for extension of the. disease with a total extent of 2.8 cm. Comment. Part E: The tumor reveals a mixed ductal and lobular morphologic appearance,. however, immunohistochemical stains for E-cadherin were performed on. representative areas and supports the presence of a lobular carcinoma. Case presented at multidisciplinary breast conference on. Specimens Received: A: Right axillary sentinel node#1. B: Right axillary sentinel node #2. C: Right axillary sentinel node #3. D: Right axillary sentinel node #4. E: Right breast partial mastectomy. F: Additional superior medial margin. Gross Description: The specimen is received in six containers each labeled with the patient' S name. and medical record number. A. Container A is further designated as 1. Right axillary sentinel node #1.'. Received fresh and placed in formalin is a 1.5 x 1.2 x 1.0 cm firm, rubbery. lymph node that is dissected and entirely submitted in cassette A1. B. Container B is further designated as 2. Right axillary sentinel node #2. Received fresh and placed in formalin is a 0.7 X 0.6 X 0.4 cm tan, rubbery lymph. node candidate that is entirely submitted in cassette B1. C. Container C is further designated as '3. Right axillary sentinel node #3.'. Received fresh and placed in formalin is a 0.9 X 0,7 X 0.4 cm tan, rubbery lymph. node candidate. It is entirely submitted in cassette C1. D. Container D is further designated as 14. Right axillary sentinel node #4. Received fresh and placed in formalin is a 0.6 x 0.5 x 0.2 cm tan, rubbery lymph. node candidate that is entirely submitted in cassette D1. E. Container E is further designated as '5. Right breast partial mastectomy'. with the paper work additionally designating 1 stitch = lateral. Received fresh. and placed in formalin is a 99.5 gram, 8.5 cm (superior to inferior) X 10.0 cm. (medial to lateral) X 3.5 cm (anterior to posterior) breast lumpectomy specimen. on a radiographic grid with a corresponding x-ray film. There is a metallic. clip located in the center of a spiculated irregularly shaped mass which. corresponds to C3-C4, D3-D4 and D5. The metallic clip is located in D4. There. is a questionable extension of the mass into grids E3-E4. A wire extends through. the center of this mass entering at B5 and terminating at F1. The specimen is. received with two sutures, long designating lateral and short designating. superior. The margins are inked as follows: superior blue, inferior green,. anterior black, posterior red, lateral violet and medial yellow. The. specimen is serially sectioned from lateral to medial into 14 slices to reveal a. 1.6 X 1.5 X 1.4 cm firm, white poorly circumscribed mass extending from slice 6. to slice 9. There is a metallic clip found on the center of this mass in slice. 8. The mass approaches the anterior margin within 0.3 cm (slice 9) and the. posterior margin within 0.6 cm (slice 7). Additionally, the lesion is 3.5 cm. from the inferior margin and 0.7 cm from the superior margin. The mass is. greater than 2 cm from both the medial and lateral margins. The wire terminates. in slice 11. The remainder of the breast tissue consists of grossly. unremarkable yellow, lobulated adipose tissue. Representative sections are. submitted as follows: E1: mass with clip (slice 8) showing approach to posterior and superior margins. E2-E3: anterior margin from slice 8. E4-E5: mass in slice 7 showing closest approach to posterior margin. E6-E7: mass in slice 6 demonstrating biopsy site changes. E8: inferior margin from slice 6. E9-E10: mass in slice 10 showing nearest approach to anterior margin. E11: posterior margin slice 7. E12-E13: posterior inferior margin slice 8. E14: posterior margin slice 9. E15: anterior margin slice 9. E16: anterior margin slice 8. E17: anterior superior margin slice 6. E18-E20: sections immediately lateral to mass (slice 5). E21-E22: sections immediately medial to mass (slice 10). E23: grossly unremarkable breast parenchyma slice 3. E24: grossly unremarkable breast parenchyma slice 12. E25: lateral margin serially sectioned (slice 1). E26: medial margin serially sectioned (slice 14). F.Container F is further designated as '3. Additionalsuperior medial margin,. short stitch marks new true margin.' Received fresh is a 38.0 gram portion of. yellow, lobulated fibroadipose tissue that measures 8.5 X 6.0 X 1.5 cm. The. short stitch designates the new true margin. This aspect is inked blue. The. specimen does not have any further orientation. The specimen is serially. sectioned to reveal that is primarily composed of yellow, lobulated adipose. tissue with a region of enhanced firm, white fibrosis measuring 2.4 X 1.5 X 1.5. cm that appears to abut the new true margin. The specimen is entirely submitted. sequentially in cassettes F1-F23 with the fibrotic region in F9-F14. Pathologist Sign Out:",BRCA,0,"The report states that all four sentinel nodes were negative for metastatic carcinoma. According to the provided rules, the absence of metastatic disease in the sentinel nodes indicates no lymph node involvement, and an N0 stage indicates no lymph node involvement.",N0,3.0
1361,TCGA-EW-A1PH.2E77693B-FAAD-4CCC-BD4F-3D2470C25143,0,"F. Pathologic Interpretation: A. BREAST, EXCISIONAL/INCISIONAL BIOPSY: - INVASIVE MAMMARY CARCINOMA, poorly differentiated, Nottingham grade 3 (3+3+2=8), 2.0 cm in greatest. dimension. - Margins are free of tumor. - Tumor cells are reported to be negative for ER, PR and Her2 by immunohistochemistry performed on patient's previous. biopsy. - See tumor summary. B. FS: SENTINEL NODE #1. - No carcinoma seen in one lymph node (0/1). - Keratin immunostain is pending. C. SENTINEL NODE #2. FS: - Metastatic carcinoma in one fymph node (1/1). - Largest metastatic deposit, 2.5 cm. - Perinodal extension is not identified. D. SENTINEL NODE #3. , FS: - No carcinoma seen in one lymph node (0/1). - Keratin immunostain is pending. E. AXILLARY CONTENT RIGHT SIDE: - No carcinoma seen in seven lymph nodes (0/7). Tumor Summary. Specimen: - Partial breast. Procedure: - Excision without wire-guided localization. Lymph Node Sampling: - Sentinel lymph node(s). - Axiliary dissection (partial or complete dissection). Specimen Integrity: - Multiple designated specimen (eg, main excision and identified margins). Specimen Size: - Greatest dimension: 7 cm. Additional dimension: 6 x 4 cm. Laterality: - Right. Tumor Size: Size of Largest Invasive Carcinoma. - Greatest dimension of largest focus of invasion over 0.1 cm: 2 cm. Additional dimensions: 2 x 1.6 cm. Tumor Focality: - Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of tumor: - Skin: Skin is not present. - Skeletal muscle: No skeletal muscle present. Ductal Carcinoma In (DCIS): No DCIS is present. Lobular Carcinoma IN Situ (LCIS): Not identified. Histologic Type of Invasive Carcinoma: - Invasive carcinoma. Histologic Grade: Nottingham Histologic Score. Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. SURGICAL PATHOL Report. Mitotic Count: Score 2. Overall Grade: Grade 3: score of 8. Margins: - Margins uninvolved by invasive carcinoma. - Distance from closest margin: 1 mm (anterior, posterior, lateral). Specify margins: Distance from superior margin: 3 mm. Distance from inferior margin: 2.5 mm. Distance from anterior margin: 1 mm. Distance from posterior margin: 1 mm. Distance from medial margin: 2 mm. Distance from lateral margin: 1 mm. Treatment Effect: Response to Presurgical (Neoadjuvant) therapy: - In the Breast: No definite response to presurgical therapy in the invasive carcinoma. - In the Lymph Nodes: No definite response to presurgical therapy in metastatic carcinoma. Lymph-Vascular Invasion: Not identified. Dermal Lymph-Vascular Invasion: No skin present. Lymph Nodes: - Number of sentinel lymph node examined: 3. - Total numbe. S examined (sentinel and Nonsentinel): 10. - Number of. in macrometastases (>0.2 cm): 1. Extrano. identified. Mest. antir vmph Nodes: Hematoxylin and eosin (H&E), one level. -aging: umor: pT1c. .gional Lymph Nodes: pN. Distant Metastasis: Not a. Anciliary Studies: Estrogen Recaptor: - Performed on arother specimen: Results: No immunoreactive tumor cells present. - tarone. ; Results: No immunoreactive tumor cells present. Her. - Performed un a wis er specimer. 1; Results: Negative (Score 0). Preliminary AJCC Classification (7th Edition) pT1c pN1a Mn/a. (Final AJCC c. tion pending evaluation of keratin stain on sentinel nodes). n'' imnohistochemicalann. of if reagents (ASRs) validated by our laboratory. These ASRs are clinirally useful indicators that do not require FDA approval. These clones are used: IDS CA. PRR 636=PR. 1485=HER2, H-. COFR. A. stains are used with formalin or molecular fixed. paraffin embedded tissue. is by Envision Method. The. results are read by a. pathologist us positive or negative. As the attending pathologist, I attest that I: (i) Examined the relevant preparation(s). for the specimen(s); and (ii) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. B. SENTINEL NODE #1. 1, FS: - Immunohistochemistry for keratin is negative for carcinoma. SURGICAL PATHOL Report. D. SENTINEL NODE #3. ). FS: Immunohistochemistry for keratin is negative for carcinoma. Intraoperative Consultation. B. Sentinel node #1 1. FS: No carcinoma seen. C. Sentinel node #2. FS: Metastatic carcinoma to one lymph node. D. Sentinel node #3. FS: No carcinoma seen. MD. Clinical History: None Provided. Operation Performed. Right breast lumpectomy with sentinel node biopsy and possible node dissection. Pre Operative Diagnosis: Breast cancer. Specimen(s) Received: A: Breast, excisional/incisional blopsy. B: Sentinel node #1. 1, FS. C: Sentinel node #2 (. FS. D: Sentinel node #3 1. 1. FS. E: Axillary content right side. Gross Description: A. Received in formalin is a 43 gram, 7.0 x 6.0 x 4.0 cm lumpectomy specimen, oriented with one stitch superipr, two stitches. lateral and three stitches deep. Resection margins are inked as follows: Superior blue, inferior green, medial red, lateral. orange, anterior yellow, posterior black. On serial sections through the specimen, there is a tan-white indurated mass. with ill-defined borders, measuring 2.0 x 2.0 x 1.6 cm. This lesion is situated less than 1 mm from the anterior resection. margin, 1 mm from the lateral resection margin, 7 mm from the medial margin, 4 mm from the deep margin, and 20 cm. from superior margin and 2.5 cm from the interior margin. No other lesions are identified. Sections submitted as. follows: 1. Lesion in relation to anterior and posterior margin. 2. Lateral margin. 3. inferior and medial margin. 4. Superior margin. 5-8. Lesion submitted in toto. 9&10. Additional sections of the specimen with fibrotic area. B. Received fresh is a segment of tan-grey soft tissue, measuring 1.0 x 1.0 x 0.4 cm. Bisected and submitted in toto in one. cassette for frozen. C. Received fresh is a segment of tan-brown soft tissue, measuring 0.7 x 0.3 x 0.2 cm. Submitted in toto in on e cassette for. frozen. D. Received fresh is a segment of tan-grey soft tissue, measuring 1.5 x 0.7 x 0.4 cm. Submitted in toto in one. cassette for. frozen. SURGICAL PATHOL Report. E. Received in formalin is a tan-yellow fibroadipose tissue, measuring 11.0 x 6.0 x 2.0 cm. Examination of the specimen. reveals multiple possible lymph nodes. Sections submitted as follows: 1-3. One lymph node bisected per cassette. 4&5. Two lymph nodes in toto per cassette. MD (.",BRCA,1,"The report states that there is metastatic carcinoma in one sentinel node (Sentinel Node #2), indicating that the N stage is N1.",N1,4.0
1061,TCGA-BH-A18T.B8FF655E-47AB-4BB0-B119-1402A335126A,1,"PATIENT HISTORY: The patient is a -year-oid female with no clinical history or LMP given. PRE-OP DIAGNOSIS: Right breast CA. POST-OP DIAGNOSIS: Same. PROCEDURE: Right segmental mastctomy, sentinel node. ADDENDA: Addendum. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controis, the test for the presence of these hormone receptor proteins is. performed by the immunoperoxidase method. and reported according to the. consensus statement on adjuvant. therapy for breast cancer, of,. A positive ER or PR tumor shows any nuclear immunostaining, and is. semiquantitated as indicated below. Semiquantitative Statement. ER negative. Percent cells staining as: (0 100%). PR negative. Percent cells staining as: (0 100%). HER-2/NEU DAKO HERCEPTEST: A WEAK TO MODERATE COMPLETE MEMBRANE STAINING IS OBSERVED IN MORE. THAN 10% OF THE TUMOR CELLS. HER-2/NEU IS INTERPRETED AS WEAKLY POSITIVE (SCORE 2+). NOTE: Her-2/Neu FISH was ordered and will be subsequently reported. The Her-2/neu and estrogeniprogesterone receptor assays were performed with FDA approved. methods. FINAL DIAGNOSIS: PART 1: BREAST, RIGHT, SEGMENTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA, 3.1 CM, POORLY DIFFERENTIATED, NOTTINGHAM SCORE - 9/9. (TUBULES = 3, NUCLEAR GRADE = 3, MITOSES = 3). B. LYMPHOVASCULAR INVASION IS IDENTIFIED. C. SEPARATE FOCI OF DUCTAL CARCINOMA IN SITU, SOLID TYPE, HIGH NUCLEAR GRADE. D. THE DUCTAL CARCINOMA IN SITU EXTENDS CLOSE (<0.1CM) TO THE POSTERIOR SURGICAL MARGIN. OF RECECTION. E. ALL SURGICAL MARGINS OF RESECTION ARE FREE OF TUMOR. F. NON-NEOPLASTIC BREAST WITH FIBROCYTIC CHANGES. PART 2: SENTINEL LYMPH NODE #1, RIGHT AXILLA, BIOPSY -. ONE (1) LYMPH NODE, NEGATIVE FOR TUMOR (0/1), (see comment). PART 3: SENTINEL LYMPH NODE #2, RIGHT AXILLA, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR, (0/1), (see comment). PART 4: NON-SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR, (0/1). COMMENT: Cytokeratin (AE1/3) stains have been performed and confirm the negative status of the sentinal lymph nodes.",BRCA,0,"The pathology report mentions that both sentinel lymph nodes (#1 and #2) were negative for tumor based on Cytokeratin (AE1/3) stains. According to the provided rules, the absence of metastatic disease in the sentinel nodes indicates no lymph node involvement. Therefore, the N stage is N0.",N0,5.0
1468,TCGA-OK-A5Q2.8F2F2141-EC62-4321-B799-054D32FEBA87,1,"Infiltrating Lobular Carcinoma. CATEGORY: BREAST INVASIVE CARCINOMA-INFILTRATING LOBULAR. CARCINOMA. FROM PRIMARY BREAST SURGERY. CLINICAL HX - Invasive lobular carcinoma. RIGHT BREAST, MASTECTOMY - Invasive lobular carcinoma, focally pleomorphic type,. 3.0cm in greatest microscopic dimension, associated with extensive duct carcinoma in-situ. (DCIS), intermediate nuclear grade, solid type with comedo necrosis. [Nottingham histologic. grading system utilized- SBR score 7; architectural grade 3, nuclear grade 2, mitotic grade 2). No. lymphatic invasion is identified. Deep margin negative for tumor. Vessel wall calcifications. Intraductal papilloma, radial scar and fibrocystic changes including sclerosing adenosis. Skin and. nipple, unremarkable. Prior biopsy site changes. RIGHT AXILLARY CONTENTS, EXCISION - Metastatic carcinoma present in two of the. thirteen lymph nodes (2/13). Largest metastatic focus measures 4mm in greatest microscopic. dimension. No extranodal extension is identified. Comment: AJCC pathologic stage pT2N1aMx. Synoptic summary will follow as an addendum. ADDENDUM 1: RIGHT BREAST, MASTECTOMY - Immunohistochemical stain for HER-2-NEU oncoprotein. is negative (performed on formalin-fixed paraffin embedded sections by manual semiquantitative. morphometric analysis with appropriate positive and negative controls). No membranous staining. is seen. The HER-2-NEU procedure was performed using monoclonal antibody 4B5 and DAB. detection system. (Staining interpretation: Weak = 1+; Moderate = 2+; Strong = 3+.). NOTE. This evaluation was performed according to ASCO/CAP guidelines: Positive HER2/neu. cases are those with strong and complete membrane staining (3+) in greater than 30% of invasive. cancer cells. Negative cases are defined as those with no staining (0) or weak, incomplete. membrane staining (1+) in any proportion of cells. Equivocal cases are those cases with strong. staining in less than or equal to 30% of cells, or less than strong but complete membrane staining. (2+) in at least 10% of cells. Immunohistochemical stains were performed on formalin-fixed. paraffin embedded tissue with appropriate positive and negative controls. ADDENDUM 2. Specimen Type - Mastectomy. Lymph node Sampling - Axillary dissection. Specimen Size. Greatest dimension 3cm. Histologic Type - Invasive lobular. Grading System - Nottingham. Tubule Formation - Minimal less than 10% (score = 3). Nuclear Pleomorphism - Moderate. increase in size, etc (score = 2). Mitotic Count - 40X objective field with a field area of 0.152. mm2: 6 to 10 mitoses per 10 HPF (score = 2). Total Nottingham Score - Grade II: 6-7 points. Margins uninvolved by invasive carcinoma. Distance from closest margin: 5mm. Deep Primary. Tumor [pT]: pT2 - Tumor greater than or equal to 2.0-5.0cm. Regional Nodes [pN]: pN1a: Metastasis in 1 to 3 axillary lymph nodes (at least 1 tumor deposit greater than 2.0mm). Number. involved: 2. Number examined: 13. Distant Metastasis [pM]: pMX - cannot be assessed. FROM DIAGNOSIS. CLINICAL HX - Right irregular mass, Right ax tail lymph node. RIGHT BREAST, 10:00. MASS, CORE BIOPSY - Invasive, lobular carcinoma with focal duct carcinoma in situ, solid. type, low nuclear grade. Intraductal papilloma involved by lobular carcinoma in-situ. RIGHT. AXILLA, LYMPH NODE, CORE BIOPSY - Lymph node with metastatic carcinoma. histologically identical to breast carcinoma. COMMENT. Prognostic/predictive markers are. being performed and results will follow as an addendum. ADDENDUM: Results of. immunoperoxidase steroid receptor protein determination on paraffin sections, visually evaluated. using DAB detection system and monoclonal antibodies (manual semiquantitative morphometric. 7. analysis): ESTROGEN RECEPTOR PROTEIN (ER- clone SP1): POSITIVE; PROGESTERONE. RECEPTOR PROTEIN (PR- clone 1E2): POSITIVE. Estimated percentage of nuclei staining. positive (ER): 100; Estimated percentage of nuclei staining positive (PR): 25. Intensity of. staining, ER: 3+ (strong). Intensity of staining, PR: 3+ (strong). Immunohistochemical stain for. HER-2-NEU oncoprotein is NEGATIVE (performed on formalin-fixed paraffin embedded. sections by manual semiquanitative morphometric analysis). No membranous staining is seen. The HER-2-NEU procedure was performed using monoclonal antibody 4B5 and DAB detection. system. 8.",BRCA,1,"The report states that metastatic carcinoma is present in two of the thirteen lymph nodes (2/13), indicating lymph node involvement and an N1 stage.",N1,6.0
